Tiziana Life Sciences Ltd. (TLSA)
NASDAQ: TLSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TLSA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $79.45M
- EPS (TTM)
- -$0.21
- Dividend yield
- None
- 52-week range
- 0.55 – 1.90
- Day range
- 0.6119 – 0.70
- Volume / Avg
- 231.24K / 606.04K
- Beta
- —
- Shares outstanding
- 128.03M
52-week range
TLSA stock today
Tiziana Life Sciences (TLSA) closed at $0.6206 on Nov 20, down 8.14% (-$0.055), versus the S&P 500's 3.70% decline. Trading was light, with 231.24K shares changing hands, about 38% of the average daily volume. At this level, TLSA sits near the bottom of its 52-week range of $0.55 to $1.90: 67.3% below the high, set on Dec 2, 2025 and 12.8% above the low.
TLSA is down 58.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 64.3%. Tiziana Life Sciences has posted a net loss over the last twelve months (EPS of -$0.21), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tiziana Life Sciences
Company profileTiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Ivor R. Elrifi Ph.D.
- Headquarters
- London
- Employees
- 10
- IPO year
- 2018
- Website
- tizianalifesciences.com
Financial highlights
Full financialsTiziana Life Sciences reported a net loss of $11.9 million, compared with a loss of $17.7 million a year earlier. Diluted earnings per share came in at -$0.11.
| Fiscal year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-11.86M | $-17.69M | $-15.40M | $-23.42M | $-26.13M |
| EPS (diluted) | $-0.11 | $-0.17 | $-0.15 | $-0.24 | $-0.16 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$8.09+1203.58%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
TLSA news
All TLSA news- Tiziana Life Sciences Ltd to Present at the Jefferies Global Healthcare Conference 2026Nasdaq
- Tiziana Life Sciences Ltd Highlights Positive Phase 2a INFORM-MS Topline Results and 12-Week Clinical Benefits of Intranasal ForalumabNasdaq
- Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal ForalumabGlobeNewswire
- Tiziana Life Sciences Ltd to Present at BIO-Europe 2026 and Host KOL WebcastNasdaq
- Tiziana Life Sciences Ltd Announces Positive Phase 2a INFORM-MS Topline ResultsNasdaq
- Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline ResultsGlobeNewswire
- Tiziana's Intranasal Foralumab Meets Primary Endpoints In Phase 2a Multiple Sclerosis TrialNasdaqTLSA, BF.A
- Tiziana Eyes Next Foralumab Milestones After Positive Progressive MS Data; Stock DownNasdaqTLSA, WSO.B
Tiziana Life Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NKTXNkarta Inc. | 1.14 | +1.34% | $81.29M | vs TLSA |
| HURATuHURA Biosciences Inc. | 1.25 | -8.09% | $82.20M | vs TLSA |
| OGIOrganigram Global Inc. | 0.583 | -7.40% | $82.27M | vs TLSA |
| ANIXAnixa Biosciences Inc. | 2.44 | -6.15% | $84.82M | vs TLSA |
| UPBUpstream Bio Inc. | 1.59 | -20.50% | $87.15M | vs TLSA |
| EQEquillium Inc. | 1.06 | -5.36% | $87.26M | vs TLSA |
| RTSNRetension Pharmaceuticals Inc. | 10.51 | -19.22% | $87.57M | vs TLSA |
| CPIXCumberland Pharmaceuticals Inc. | 5.84 | -7.30% | $87.57M | vs TLSA |
Indexes, lists and sector
Tiziana Life Sciences stock FAQ
What is Tiziana Life Sciences's stock price today?
TLSA last traded at $0.6206 as of Nov 20, 4:00 PM EST, down 8.14% on the day. Prices are delayed at least 15 minutes.
Does Tiziana Life Sciences pay a dividend?
No. Tiziana Life Sciences does not currently pay a regular cash dividend.
Who is Tiziana Life Sciences's CEO?
Dr. Ivor R. Elrifi Ph.D. is the chief executive officer of Tiziana Life Sciences Ltd., which has about 10 employees.
Has TLSA ever split its stock?
Yes. The most recent TLSA stock split was a 2499-for-1000 split on Jul 31, 2020, one of 2 splits on record.
What is the TLSA 52-week high?
The 52-week high for TLSA is $1.90 and the 52-week low is $0.55. The stock is currently 67.3% below its high.